Matthews China Innovators Active ETF (MCHS)

MCHS represents an active bet on Chinese innovation. Rather than accepting the returns of the broad Chinese market (as a passive fund like MCHI would), Matthews’ team selects roughly 50 to 100 companies they believe offer superior growth and competitive advantage. The fund operates on a simple thesis: not all Chinese companies are created equal, and disciplined security selection can identify which ones will outperform.

Matthews International Capital Management is an Asia-focused investment firm with deep experience in China markets. The firm’s selection criteria emphasize companies that are category leaders, possess proprietary technology or intellectual property, command pricing power, and are led by capable management teams with a track record of creating shareholder value. This naturally tilts the portfolio toward technology, internet, healthcare, and consumer sectors—industries where innovation confers durable competitive advantages—rather than toward state-owned enterprises and commodity-linked cyclical firms that dominate broad China indices.

The active-management fee is substantial: typically 0.7 to 1.0 percent annually or higher, versus 0.55 to 0.75 percent for passive China ETFs. This difference must be justified by outperformance. The historical track record of active managers in China is decidedly mixed. China’s markets are less transparent than developed markets, information asymmetries are larger, and sudden regulatory shifts can invalidate months of analysis. However, China’s analyst coverage and institutional research infrastructure remain less mature than in the United States, which means an experienced team on the ground may genuinely find mispricings that passive investors miss.

By holding 50 to 100 names instead of the 700 in a passive China index, MCHS accepts concentration and volatility. A single misjudged position or a sector rotation against growth stocks can meaningfully damage performance. The fund’s explicit tilt toward technology and innovation means it will underperform during periods when the market rewards value stocks or dividend payers. This is not accidental; it is the core bet. The investor explicitly accepts this concentrated, growth-oriented bet in exchange for the promise of alpha.

Regulatory risk cuts both ways for MCHS. All China-focused funds face the risk that the government will restrict foreign investment, ban sectors, or tighten capital flows. But MCHS’s concentrated holdings in growth-oriented tech and internet companies may face particular regulatory scrutiny, as the Chinese government has periodically tightened oversight of fintech, online education, and internet platforms. Geopolitical tensions between the US and China—over Taiwan, trade, or technology—could also hit these holdings.

MCHS is designed for investors with higher risk tolerance, conviction that active management can identify outperforming companies, and willingness to accept the higher fee. It suits those with longer time horizons (five to ten years or more) and those seeking growth-oriented China exposure. It is unsuitable for conservative investors, those seeking lowest-cost access, or those skeptical of active stock-pickers.

To evaluate MCHS: obtain the prospectus and fact sheet to see current holdings. Are the top ten positions recognizable Chinese tech or consumer brands, or obscure companies? Compare three-, five-, and ten-year returns against passive China ETFs and the MSCI China Index—the ultimate test of whether active management is earning its fee. Examine portfolio turnover: high turnover can signal excessive trading costs; very low turnover suggests the manager is underperforming or not actively managing. Assess your own conviction on Chinese growth stocks and your comfort with a rapidly shifting regulatory environment.